ParkinsonFranceV1, PascalFrancis, Curation, bibRecord, 000655

Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats

Identifieur interne : 000655 ( PascalFrancis/Curation ); précédent : 000654; suivant : 000656

Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats

Auteurs : Roberto Coccurello [France] ; Nathalie Breysse [France] ; Marianne Amalric [France]

Source :

Neuropsychopharmacology : (New York, NY) [ 0893-133X ] ; 2004.

RBID : Pascal:04-0439077

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Récepteur métabotropique, Récepteur glutamate, Animal, Rat, Temps réaction, Antagoniste, Récepteur adénosinique A2A, Antiparkinsonien, Mécanisme action.

English descriptors

KwdEn :
- A2A adenosine receptor, Animal, Antagonist, Antiparkinson agent, Glutamate receptor, Mechanism of action, Metabotropic receptor, Parkinson disease, Rat, Reaction time.

Abstract

Recent evidence suggest that antagonism of adenosine A_2A receptors represent an alternative therapeutic approach to Parkinson's disease (PD). Coactivation of A_2A and the glutamate subtype 5 metabotropic receptors (mGlu₅) synergistically stimulates DARPP-32 phosphorylation and c-fos expression in the striatum. This study therefore tested the effects of a joint blockade of these receptors to alleviate the motor dysfunction in a rat model of PD. 6-Hydroxydopamine infusions in the striatum produced akinetic deficits in rats trained to release a lever after a stimulus in a reaction time (RT) task. At 2 weeks after the lesion, A_2A and mGlus receptors selective antagonists 8-(3-chlorostyryl)caffeine (CSC) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were administered daily for 3 weeks either as a single or joint treatment. Injections of CSC (1.25 mg/kg) and MPEP (1.5 mg/kg) separately or in combination reduced the increase of delayed responses and RTs induced by 6-OHDA lesions, while the same treatment had no effect in controls. Furthermore, coadministration of lower doses of 0.625 mg/kg CSC and 0.375 mg/kg MPEP noneffective as a single treatment promoted a full and immediate recovery of akinesia, which was found to be more efficient than the separate blockade of these receptors. These results demonstrate that the combined inactivation of A_2A and mGlu₅ receptor potentiate their beneficial effects supporting this pharmacological strategy as a promising anti-Parkinsonian therapy.

A01	`01`	`1`		`@0 0893-133X`
A02	`01`			`@0 NEROEW`
A03		`1`		`@0 Neuropsychopharmacology : (NY NY)`
A05				`@2 29`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Simultaneous blockade of adenosine A_2A and metabotropic glutamate mGlu₅ receptors increase their efficacy in reversing Parkinsonian deficits in rats`
A11	`01`	`1`		`@1 COCCURELLO (Roberto)`
A11	`02`	`1`		`@1 BREYSSE (Nathalie)`
A11	`03`	`1`		`@1 AMALRIC (Marianne)`
A14	`01`			`@1 Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence @2 Marseille @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A20				`@1 1451-1461`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21601 @5 354000113850450060`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.3/4`
A47	`01`	`1`		`@0 04-0439077`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuropsychopharmacology : (New York, NY)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Recent evidence suggest that antagonism of adenosine A_2A receptors represent an alternative therapeutic approach to Parkinson's disease (PD). Coactivation of A_2A and the glutamate subtype 5 metabotropic receptors (mGlu₅) synergistically stimulates DARPP-32 phosphorylation and c-fos expression in the striatum. This study therefore tested the effects of a joint blockade of these receptors to alleviate the motor dysfunction in a rat model of PD. 6-Hydroxydopamine infusions in the striatum produced akinetic deficits in rats trained to release a lever after a stimulus in a reaction time (RT) task. At 2 weeks after the lesion, A_2A and mGlus receptors selective antagonists 8-(3-chlorostyryl)caffeine (CSC) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were administered daily for 3 weeks either as a single or joint treatment. Injections of CSC (1.25 mg/kg) and MPEP (1.5 mg/kg) separately or in combination reduced the increase of delayed responses and RTs induced by 6-OHDA lesions, while the same treatment had no effect in controls. Furthermore, coadministration of lower doses of 0.625 mg/kg CSC and 0.375 mg/kg MPEP noneffective as a single treatment promoted a full and immediate recovery of akinesia, which was found to be more efficient than the separate blockade of these receptors. These results demonstrate that the combined inactivation of A_2A and mGlu₅ receptor potentiate their beneficial effects supporting this pharmacological strategy as a promising anti-Parkinsonian therapy.
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 10`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 10`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 10`
C03	`02`	`X`	`FRE`	`@0 Récepteur métabotropique @5 12`
C03	`02`	`X`	`ENG`	`@0 Metabotropic receptor @5 12`
C03	`02`	`X`	`SPA`	`@0 Receptor metabotropico @5 12`
C03	`03`	`X`	`FRE`	`@0 Récepteur glutamate @5 14`
C03	`03`	`X`	`ENG`	`@0 Glutamate receptor @5 14`
C03	`03`	`X`	`SPA`	`@0 Receptor glutámato @5 14`
C03	`04`	`X`	`FRE`	`@0 Animal @5 15`
C03	`04`	`X`	`ENG`	`@0 Animal @5 15`
C03	`04`	`X`	`SPA`	`@0 Animal @5 15`
C03	`05`	`X`	`FRE`	`@0 Rat @5 16`
C03	`05`	`X`	`ENG`	`@0 Rat @5 16`
C03	`05`	`X`	`SPA`	`@0 Rata @5 16`
C03	`06`	`X`	`FRE`	`@0 Temps réaction @5 17`
C03	`06`	`X`	`ENG`	`@0 Reaction time @5 17`
C03	`06`	`X`	`SPA`	`@0 Tiempo reacción @5 17`
C03	`07`	`X`	`FRE`	`@0 Antagoniste @5 18`
C03	`07`	`X`	`ENG`	`@0 Antagonist @5 18`
C03	`07`	`X`	`SPA`	`@0 Antagonista @5 18`
C03	`08`	`X`	`FRE`	`@0 Récepteur adénosinique A2A @5 19`
C03	`08`	`X`	`ENG`	`@0 A2A adenosine receptor @5 19`
C03	`08`	`X`	`SPA`	`@0 Receptor adenosínico A2A @5 19`
C03	`09`	`X`	`FRE`	`@0 Antiparkinsonien @5 20`
C03	`09`	`X`	`ENG`	`@0 Antiparkinson agent @5 20`
C03	`09`	`X`	`SPA`	`@0 Antiparkinsoniano @5 20`
C03	`10`	`X`	`FRE`	`@0 Mécanisme action @5 21`
C03	`10`	`X`	`ENG`	`@0 Mechanism of action @5 21`
C03	`10`	`X`	`SPA`	`@0 Mecanismo acción @5 21`
C07	`01`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`01`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 62`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 62`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 62`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 63`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 63`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 63`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 64`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 64`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 64`
C07	`07`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 65`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 65`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 65`
C07	`08`	`X`	`FRE`	`@0 Système nerveux pathologie @5 66`
C07	`08`	`X`	`ENG`	`@0 Nervous system diseases @5 66`
C07	`08`	`X`	`SPA`	`@0 Sistema nervioso patología @5 66`
N21				`@1 250`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D79

Links to Exploration step

Pascal:04-0439077

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Simultaneous blockade of adenosine A<sub>2A</sub>
 and metabotropic glutamate mGlu<sub>5</sub>
 receptors increase their efficacy in reversing Parkinsonian deficits in rats</title>
<author><name sortKey="Coccurello, Roberto" sort="Coccurello, Roberto" uniqKey="Coccurello R" first="Roberto" last="Coccurello">Roberto Coccurello</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Breysse, Nathalie" sort="Breysse, Nathalie" uniqKey="Breysse N" first="Nathalie" last="Breysse">Nathalie Breysse</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Amalric, Marianne" sort="Amalric, Marianne" uniqKey="Amalric M" first="Marianne" last="Amalric">Marianne Amalric</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0439077</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0439077 INIST</idno>
<idno type="RBID">Pascal:04-0439077</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D79</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000655</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Simultaneous blockade of adenosine A<sub>2A</sub>
 and metabotropic glutamate mGlu<sub>5</sub>
 receptors increase their efficacy in reversing Parkinsonian deficits in rats</title>
<author><name sortKey="Coccurello, Roberto" sort="Coccurello, Roberto" uniqKey="Coccurello R" first="Roberto" last="Coccurello">Roberto Coccurello</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Breysse, Nathalie" sort="Breysse, Nathalie" uniqKey="Breysse N" first="Nathalie" last="Breysse">Nathalie Breysse</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Amalric, Marianne" sort="Amalric, Marianne" uniqKey="Amalric M" first="Marianne" last="Amalric">Marianne Amalric</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuropsychopharmacology : (New York, NY)</title>
<title level="j" type="abbreviated">Neuropsychopharmacology : (NY NY)</title>
<idno type="ISSN">0893-133X</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuropsychopharmacology : (New York, NY)</title>
<title level="j" type="abbreviated">Neuropsychopharmacology : (NY NY)</title>
<idno type="ISSN">0893-133X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>A2A adenosine receptor</term>
<term>Animal</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Glutamate receptor</term>
<term>Mechanism of action</term>
<term>Metabotropic receptor</term>
<term>Parkinson disease</term>
<term>Rat</term>
<term>Reaction time</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Récepteur métabotropique</term>
<term>Récepteur glutamate</term>
<term>Animal</term>
<term>Rat</term>
<term>Temps réaction</term>
<term>Antagoniste</term>
<term>Récepteur adénosinique A2A</term>
<term>Antiparkinsonien</term>
<term>Mécanisme action</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Recent evidence suggest that antagonism of adenosine A<sub>2A</sub>
 receptors represent an alternative therapeutic approach to Parkinson's disease (PD). Coactivation of A<sub>2A</sub>
 and the glutamate subtype 5 metabotropic receptors (mGlu<sub>5</sub>
) synergistically stimulates DARPP-32 phosphorylation and c-fos expression in the striatum. This study therefore tested the effects of a joint blockade of these receptors to alleviate the motor dysfunction in a rat model of PD. 6-Hydroxydopamine infusions in the striatum produced akinetic deficits in rats trained to release a lever after a stimulus in a reaction time (RT) task. At 2 weeks after the lesion, A<sub>2A</sub>
 and mGlus receptors selective antagonists 8-(3-chlorostyryl)caffeine (CSC) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were administered daily for 3 weeks either as a single or joint treatment. Injections of CSC (1.25 mg/kg) and MPEP (1.5 mg/kg) separately or in combination reduced the increase of delayed responses and RTs induced by 6-OHDA lesions, while the same treatment had no effect in controls. Furthermore, coadministration of lower doses of 0.625 mg/kg CSC and 0.375 mg/kg MPEP noneffective as a single treatment promoted a full and immediate recovery of akinesia, which was found to be more efficient than the separate blockade of these receptors. These results demonstrate that the combined inactivation of A<sub>2A</sub>
 and mGlu<sub>5</sub>
 receptor potentiate their beneficial effects supporting this pharmacological strategy as a promising anti-Parkinsonian therapy.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0893-133X</s0>
</fA01>
<fA02 i1="01"><s0>NEROEW</s0>
</fA02>
<fA03 i2="1"><s0>Neuropsychopharmacology : (NY NY)</s0>
</fA03>
<fA05><s2>29</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Simultaneous blockade of adenosine A<sub>2A</sub>
 and metabotropic glutamate mGlu<sub>5</sub>
 receptors increase their efficacy in reversing Parkinsonian deficits in rats</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>COCCURELLO (Roberto)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BREYSSE (Nathalie)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>AMALRIC (Marianne)</s1>
</fA11>
<fA14 i1="01"><s1>Laboratoire de Neurobiologie de la Cognition, CNRS and Université de Provence</s1>
<s2>Marseille</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>1451-1461</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21601</s2>
<s5>354000113850450060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.3/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0439077</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuropsychopharmacology : (New York, NY)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Recent evidence suggest that antagonism of adenosine A<sub>2A</sub>
 receptors represent an alternative therapeutic approach to Parkinson's disease (PD). Coactivation of A<sub>2A</sub>
 and the glutamate subtype 5 metabotropic receptors (mGlu<sub>5</sub>
) synergistically stimulates DARPP-32 phosphorylation and c-fos expression in the striatum. This study therefore tested the effects of a joint blockade of these receptors to alleviate the motor dysfunction in a rat model of PD. 6-Hydroxydopamine infusions in the striatum produced akinetic deficits in rats trained to release a lever after a stimulus in a reaction time (RT) task. At 2 weeks after the lesion, A<sub>2A</sub>
 and mGlus receptors selective antagonists 8-(3-chlorostyryl)caffeine (CSC) and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were administered daily for 3 weeks either as a single or joint treatment. Injections of CSC (1.25 mg/kg) and MPEP (1.5 mg/kg) separately or in combination reduced the increase of delayed responses and RTs induced by 6-OHDA lesions, while the same treatment had no effect in controls. Furthermore, coadministration of lower doses of 0.625 mg/kg CSC and 0.375 mg/kg MPEP noneffective as a single treatment promoted a full and immediate recovery of akinesia, which was found to be more efficient than the separate blockade of these receptors. These results demonstrate that the combined inactivation of A<sub>2A</sub>
 and mGlu<sub>5</sub>
 receptor potentiate their beneficial effects supporting this pharmacological strategy as a promising anti-Parkinsonian therapy.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>10</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Récepteur métabotropique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Metabotropic receptor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Receptor metabotropico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récepteur glutamate</s0>
<s5>14</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Glutamate receptor</s0>
<s5>14</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Receptor glutámato</s0>
<s5>14</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Animal</s0>
<s5>15</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Animal</s0>
<s5>15</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Animal</s0>
<s5>15</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Rat</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Rat</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Rata</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Temps réaction</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Reaction time</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tiempo reacción</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Récepteur adénosinique A2A</s0>
<s5>19</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>A2A adenosine receptor</s0>
<s5>19</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Receptor adenosínico A2A</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Mécanisme action</s0>
<s5>21</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Mechanism of action</s0>
<s5>21</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Mecanismo acción</s0>
<s5>21</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>62</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>62</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>63</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>63</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>63</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>64</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>64</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>64</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>65</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>65</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>65</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>66</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>66</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>66</s5>
</fC07>
<fN21><s1>250</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000655 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000655 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0439077
   |texte=   Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats

Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri